FP7Реинтеграция2011–2015

BIONANOMUTT · Multi-compartmental Biomolecular Nanocarriers for Multi-modal Targeted Therapies

7РП — „Хора“ (Действия „Мария Кюри“)

Период
2011-10-01 → 2015-09-30
Финансиране от ЕС
100 000 €
Участници
1
Схема
MC-CIG

Линиите свързват координатора с партньорите.

Накратко на български

Наночастици от липиди и протеини се разработват за пренос на трудно разтворими лекарства директно до клетките, например при рак на пикочния мехур. Това помага за по-точното насочване на терапията към туморните клетки и контролирането на освобождаването на лекарството.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Multi-compartmental Biomolecular Nanocarriers for Multi-modal Targeted Therapies

During the BioNanoMuTT project we have been developing multifunctional self-assembled nanoparticle structures for application in biomedical drug delivery applications. We have successfully formulated a range of poorly water soluble drugs into lipid bilayer nanodisc particles without significant perturbation of the nanodisc structure or that of its stabilising protein belt. By investigation of 12 different poorly water soluble drugs, we found a correlation between the ability of drugs to thin and soften the lipid bilayer membrane and their drug loading efficiency in nanodisc systems. Drug release profiles from nanodiscs were tuneable by modulation of their lipid composition. Nanodiscs could be further modulated for traceable delivery by enzymatic labelling of the scaffold protein; these nanodiscs were used to demonstrate uptake into HELA cells. Size-limited nanoscale vesicle clusters have also been developed and characterised by the DNA-mediated adhesion of Janus-textured liposomes composed of CL/DOPC/DPPC/cholesterol mixtures; these structures could be further functionalised with stealth properties by inclusion of DOPE-PEG2000 lipids, which do not inhibit nanocluster formation. pH-responsive i-motif sequences also allow pH-triggered disassembly of DNA-linked vesicles. Towards applications in treatment of superficial bladder cancer we have screened for and characterised novel specific binding reagents with nM binding affinities for known tumour biomarkers, including FGFR1 and FGFR3. These reagents were shown to be able to target vesicle nanoparticles to receptor upregulating cell lines, compared to negligible uptake in control cell lines. Results gained in this project have supported the successful application for further research funding from UK research councils, charities and industry. Dissemination activities have included two public lectures at science cafes in the West Yorkshire region, Art-Science collaborative projects with BioLeeds including a comparative exploration of biological and modern architecture, and coverage in the scientific media of our DNA-linked vesicle work in an article in Lab Times magazine. Knowledge transfer to the host institution was primarily conducted through internal seminars, a workshop on biomembranes and teaching activities from levels one through to five on chemistry and nanotechnology degree programmes. Over the course of this career integration grant project, the Beales group has grown in size to 5 PhD students, 4 PDRAs and 3 project students including the establishment of productive collaborations in Leeds, the UK and internationally which will continue beyond the funding period of this project. Successful EU reintegration is demonstrated by Dr Beales attaining a permanent tenured position as a lecturer with his own laboratory in the School of Chemistry at the University of Leeds.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Nanomedicine is an interdisciplinary field of research that aims to use nanotechnology to improve the pharmacokinetic profile of therapeutics and/or the contrast and information from medical imaging and diagnostics. The advances in medical treatments that nanomedicine strategies will provide will have a significant socioeconomic impact for the E.U. and is particularly timely due to the aging populations in E.U. member states. This work will use a multi-strategy approach to design novel multicompartmental, multifunctional nanoarchitectures for nanomedicine applications. Lipid nanodiscs will be evaluated as a novel hydrophobic drug carrier and the versatility of the scaffold protein for these discs will be explored by assessing its capacity to form similar complexes with synthetic block copolymers. Multicompartmental, size-limited nanostructures will be developed by using the self-organisation of functional amphiphiles into anisotropic subunits as building blocks for superstructures of greater complexity and functionality. The basic building blocks explored will consist of liposomes, polymersomes and hydrid lipopolymersome structures as well as protein-stabilised lipid nanodiscs. This project will also explore incorporating quantum dots into these nanoarchitectures as an added imaging modality. Finally, through multidisciplinary collaboration of basic scientists through to clinicians, an adjuvant nanomedicine therapy will be developed for treatment of superficial bladder cancers. These therapeutic nanoparticles will contain therapeutic, imaging and active targeting functionalities to remove residual malignant cells following the surgical resection of tumours.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз